Amedeo Smart

Free Medical Literature Service

 

Amedeo

Colorectal Neoplasms
  Free Subscription

Articles published in
Clin Cancer Res
    November 2024
  1. NAKAMURA Y, Kaneva K, Lo C, Neems D, et al
    A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan.
    Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-2396.
    >> Share

    October 2024
  2. MACFARLAND SP, Becktell K, Schneider KW, Kuiper RP, et al
    Pediatric Cancer Screening in Hereditary Gastrointestinal Cancer Risk Syndromes: An Update from the AACR Childhood Cancer Predisposition Working Group.
    Clin Cancer Res. 2024;30:4566-4571.
    >> Share

  3. ANDERSSON A, Escriva Conde M, Surova O, Vermeulen P, et al
    Spatial Transcriptome Mapping of the Desmoplastic Growth Pattern of Colorectal Liver Metastases by In Situ Sequencing Reveals a Biologically Relevant Zonation of the Desmoplastic Rim.
    Clin Cancer Res. 2024;30:4517-4529.
    >> Share

    September 2024
  4. LEE HM, Saw AK, Morris VK, Napolitano S, et al
    Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated colorectal cancer.
    Clin Cancer Res. 2024 Sep 13. doi: 10.1158/1078-0432.CCR-24-1166.
    >> Share

    August 2024
  5. IIDA N, Imai M, Okamoto W, Kato T, et al
    Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
    Clin Cancer Res. 2024 Aug 20:OF1-OF12. doi: 10.1158/1078-0432.CCR-24-1023.
    >> Share

  6. DAS A, MacFarland SP, Meade J, Hansford JR, et al
    Clinical Updates and Surveillance Recommendations for DNA Replication Repair Deficiency Syndromes in Children and Young Adults.
    Clin Cancer Res. 2024;30:3378-3387.
    >> Share

  7. NAKAMURA Y, Tsukada Y, Matsuhashi N, Murano T, et al
    Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay.
    Clin Cancer Res. 2024 Aug 7. doi: 10.1158/1078-0432.CCR-24-1651.
    >> Share

  8. CHANG W, Zhang Z, Jia B, Ding K, et al
    A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study.
    Clin Cancer Res. 2024;30:3337-3348.
    >> Share

    June 2024
  9. JOHANSEN AM, Forsythe SD, McGrath CT, Barker G, et al
    TGFbeta in pancreas and colorectal cancer: opportunities to overcome therapeutic resistance.
    Clin Cancer Res. 2024 Jun 25. doi: 10.1158/1078-0432.CCR-24-0468.
    >> Share

  10. LENTZ RW, Friedrich TJ, Blatchford PJ, Jordan KR, et al
    A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite stable colorectal cancer.
    Clin Cancer Res. 2024 Jun 13. doi: 10.1158/1078-0432.CCR-24-0090.
    >> Share

  11. SLATER S, Bryant A, Aresu M, Begum R, et al
    Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study.
    Clin Cancer Res. 2024 Jun 12. doi: 10.1158/1078-0432.CCR-24-0226.
    >> Share

    May 2024
  12. FUSCO MJ, Casak SJ, Mushti SL, Cheng J, et al
    FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
    Clin Cancer Res. 2024 May 29. doi: 10.1158/1078-0432.CCR-24-0281.
    >> Share

  13. VOISIN A, Terret C, Schiffler C, Bidaux AS, et al
    Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial.
    Clin Cancer Res. 2024;30:2111-2120.
    >> Share

  14. LOREE JM, Titmuss E, Topham JT, Kennecke HF, et al
    Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial.
    Clin Cancer Res. 2024 May 10. doi: 10.1158/1078-0432.CCR-24-0268.
    >> Share

  15. PARIKH AR, Chee BH, Tsai J, Rich TA, et al
    Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Clin Cancer Res. 2024 May 2. doi: 10.1158/1078-0432.CCR-23-3660.
    >> Share

  16. WU C, Pai RK, Kosiorek H, Banerjee I, et al
    Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC.
    Clin Cancer Res. 2024;30:1811-1821.
    >> Share

  17. KHUSHMAN MM, Toboni MD, Xiu J, Manne U, et al
    Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
    Clin Cancer Res. 2024;30:1906-1915.
    >> Share

    April 2024
  18. WILBUR HC, Le DT, Agarwal P
    Immunotherapy of MSI Cancer: Facts and Hopes.
    Clin Cancer Res. 2024;30:1438-1447.
    >> Share

  19. MOUILLET-RICHARD S, Cazelles A, Sroussi M, Gallois C, et al
    Clinical challenges of consensus molecular subtype CMS4 colon cancer in the era of precision medicine.
    Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-3964.
    >> Share

    March 2024
  20. HARROLD E, Keane F, Walch H, Chou JF, et al
    Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.
    Clin Cancer Res. 2024 Mar 19. doi: 10.1158/1078-0432.CCR-23-4005.
    >> Share

  21. MALVIYA G, Lannagan TRM, Johnson E, Mackintosh A, et al
    Noninvasive Stratification of Colon Cancer by Multiplex PET Imaging.
    Clin Cancer Res. 2024 Mar 17:OF1-OF12. doi: 10.1158/1078-0432.CCR-23-1063.
    >> Share

  22. STEBBING J, Bullock AJ
    Polo-like kinase 1 inhibition in KRAS-mutated metastatic colorectal cancer.
    Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-24-0251.
    >> Share

    February 2024
  23. HEDAYAT S, Cascione L, Cunningham D, Schirripa M, et al
    Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652-3p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer.
    Clin Cancer Res. 2024 Feb 20. doi: 10.1158/1078-0432.CCR-23-2748.
    >> Share

  24. ROMESSER PB, Capdevila J, Garcia-Carbonero R, Philip T, et al
    A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.
    Clin Cancer Res. 2024;30:695-702.
    >> Share

  25. SINGH H, Sahgal P, Kapner K, Corsello SM, et al
    RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer.
    Clin Cancer Res. 2024 Feb 12. doi: 10.1158/1078-0432.CCR-23-2581.
    >> Share

    January 2024
  26. STAHLER A, Kind AJ, Sers C, Mamlouk S, et al
    Negative hyperselection of resistance mutations for panitumumab maintenance in RAS wild-type metastatic colorectal cancer (PanaMa phase II trial, AIO KRK 0212).
    Clin Cancer Res. 2024 Jan 30. doi: 10.1158/1078-0432.CCR-23-3023.
    >> Share

  27. AHN DH, Barzi A, Ridinger M, Samuelsz E, et al
    Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-line Treatment of KRAS-mutant Metastatic Colorectal Cancer: A Phase 1b Clinical Study.
    Clin Cancer Res. 2024 Jan 17. doi: 10.1158/1078-0432.CCR-23-3053.
    >> Share

  28. RAGHAV KPS, Loree JM, Kopetz S
    PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room.
    Clin Cancer Res. 2024;30:260-262.
    >> Share

  29. SOLAR VASCONCELOS JP, Chen N, Titmuss E, Tu D, et al
    Transverse colon primary tumor location as a biomarker in metastatic colorectal cancer: A pooled analysis of CCTG/AGITG CO.17 and CO.20 randomized clinical trials.
    Clin Cancer Res. 2024 Jan 3. doi: 10.1158/1078-0432.CCR-23-3275.
    >> Share

    December 2023
  30. OKUMA HS, Watanabe K, Tsuchihashi K, Machida R, et al
    Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).
    Clin Cancer Res. 2023;29:5079-5086.
    >> Share

    November 2023
  31. HAJJAR R, Oliero M, Fragoso G, Ajayi AS, et al
    Modulating gut microbiota prevents anastomotic leak to reduce local implantation and dissemination of colorectal cancer cells after surgery.
    Clin Cancer Res. 2023 Nov 27. doi: 10.1158/1078-0432.CCR-23-1601.
    >> Share

  32. DENG N, Reyes-Uribe L, Fahrmann JF, Thoman WS, et al
    Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome.
    Clin Cancer Res. 2023;29:4361-4372.
    >> Share

    October 2023
  33. LI J, Hu H, Qin G, Bai F, et al
    Biomarkers of Pathological Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair Deficiency Colorectal Cancer.
    Clin Cancer Res. 2023 Oct 31. doi: 10.1158/1078-0432.CCR-23-2213.
    >> Share

  34. SABERZADEH-ARDESTANI B, Graham RP, McMahon S, Ahanonu E, et al
    Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair-deficient, Advanced Colorectal Carcinomas.
    Clin Cancer Res. 2023;29:4268-4277.
    >> Share

  35. GOSENS KCM, van der Burg SH, Welters MJP, Boekestijn S, et al
    Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV+ Men.
    Clin Cancer Res. 2023;29:4109-4117.
    >> Share

    September 2023
  36. JANGRA R, Dhani NC
    Re-routing the GPS directing immunotherapy in endometrial cancer.
    Clin Cancer Res. 2023 Sep 12. doi: 10.1158/1078-0432.CCR-23-1953.
    >> Share

    August 2023
  37. RANDON G, Nakamura Y, Yaeger R, Lonardi S, et al
    Negative hyper-selection of patients with HER2-positive and RAS wild-type metastatic colorectal cancer receiving dual HER2 blockade: the PRESSING-HER2 study.
    Clin Cancer Res. 2023 Aug 23:CCR-23-1379. doi: 10.1158/1078-0432.CCR-23-1379.
    >> Share

  38. RANDON G, Pietrantonio F
    Towards multiomics-based dissection of anti-EGFR sensitivity in colorectal cancer.
    Clin Cancer Res. 2023 Aug 18:CCR-23-1954. doi: 10.1158/1078-0432.CCR-23-1954.
    >> Share

    July 2023
  39. FOOTE MB, Walch H, Kemel Y, Vakiani E, et al
    The Impact of Germline Alterations in Appendiceal Adenocarcinoma.
    Clin Cancer Res. 2023;29:2631-2637.
    >> Share

  40. GALLOIS C, Landi M, Taieb J, Sroussi M, et al
    Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2023 Jul 13:CCR-22-3964. doi: 10.1158/1078-0432.CCR-22-3964.
    >> Share

  41. PATELLI G, Mauri G, Tosi F, Amatu A, et al
    Circulating tumor DNA to drive treatment in metastatic colorectal cancer.
    Clin Cancer Res. 2023 Jul 12:CCR-23-0079. doi: 10.1158/1078-0432.CCR-23-0079.
    >> Share

    June 2023
  42. WILLIAMS CJM, Elliott F, Sapanara N, Aghaei F, et al
    Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer.
    Clin Cancer Res. 2023 Jun 26:CCR-23-0859. doi: 10.1158/1078-0432.CCR-23-0859.
    >> Share

  43. OAKNIN A, Pothuri B, Gilbert L, Sabatier R, et al
    Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
    Clin Cancer Res. 2023 Jun 26:CCR-22-3915. doi: 10.1158/1078-0432.CCR-22-3915.
    >> Share

  44. FOOTE MB, Argiles G, Rousseau B, Segal NH, et al
    Facts and hopes in colorectal cancer immunotherapy.
    Clin Cancer Res. 2023 Jun 16:CCR-22-2176. doi: 10.1158/1078-0432.CCR-22-2176.
    >> Share

  45. CASAK SJ, Horiba MN, Yuan M, Cheng J, et al
    FDA Approval Summary: Tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2 positive RAS wild type colorectal cancer.
    Clin Cancer Res. 2023 Jun 15:CCR-23-1041. doi: 10.1158/1078-0432.CCR-23-1041.
    >> Share

  46. WANG QL, Ma C, Yuan C, Shi Q, et al
    Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).
    Clin Cancer Res. 2023 Jun 8:OF1-OF10. doi: 10.1158/1078-0432.CCR-23-0447.
    >> Share

    May 2023
  47. WANG QL, Ma C, Yuan C, Shi Q, et al
    Plasma 25-hydroxyvitamin D levels and survival in stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).
    Clin Cancer Res. 2023 May 11:CCR-23-0447. doi: 10.1158/1078-0432.CCR-23-0447.
    >> Share

  48. SCHOEN RE, Boardman LA, Cruz-Correa M, Bansal A, et al
    Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.
    Clin Cancer Res. 2023;29:1678-1688.
    >> Share

    April 2023
  49. NAPOLITANO S, Woods M, Lee HM, De Falco V, et al
    Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer.
    Clin Cancer Res. 2023 Apr 11:CCR-22-3894. doi: 10.1158/1078-0432.CCR-22-3894.
    >> Share

  50. ANTONIOTTI C, Boccaccino A, Seitz R, Giordano M, et al
    An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.
    Clin Cancer Res. 2023 Apr 6:CCR-22-3878. doi: 10.1158/1078-0432.CCR-22-3878.
    >> Share

    March 2023
  51. DING N, You AB, Yang H, Hu GS, et al
    A tumor suppressive-molecular axis EP300/circRERE/miR-6837-3p/MAVS activates type I interferon pathway and anti-tumor immunity to suppress colorectal cancer.
    Clin Cancer Res. 2023 Mar 23:CCR-22-3836. doi: 10.1158/1078-0432.CCR-22-3836.
    >> Share

  52. RAY AL, Saunders AS, Nofchissey RA, Reidy MA, et al
    Granulocyte colony stimulating factor is a novel mediator of T cell suppression and an immunotherapeutic target for women with colon cancer.
    Clin Cancer Res. 2023 Mar 23:CCR-22-3918. doi: 10.1158/1078-0432.CCR-22-3918.
    >> Share

    January 2023
  53. JANSSENS K, Vanhoutte G, Lybaert W, Demey W, et al
    NPY methylated ctDNA is a promising biomarker for treatment response monitoring in metastatic colorectal cancer.
    Clin Cancer Res. 2023 Jan 30:CCR-22-1500. doi: 10.1158/1078-0432.CCR-22-1500.
    >> Share

  54. ELURI M, Kopetz S, Parseghian CM
    Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic Response.
    Clin Cancer Res. 2023;29:302-304.
    >> Share

  55. TAN L, Tran B, Tie J, Markman B, et al
    Phase Ib/II Trial of BRAF and EGFR inhibition in BRAFV600E metastatic colorectal cancer and other cancers: EVICT (Erlotinib and Vemurafenib In Combination Trial).
    Clin Cancer Res. 2023 Jan 13:CCR-22-3094. doi: 10.1158/1078-0432.CCR-22-3094.
    >> Share

  56. LETO SM, Ferri M, Sassi F, Zanella ER, et al
    Synthetic lethal interaction with BCL-XL blockade deepens response to cetuximab in patient-derived models of metastatic colorectal cancer.
    Clin Cancer Res. 2023 Jan 9:CCR-22-2550. doi: 10.1158/1078-0432.CCR-22-2550.
    >> Share

    December 2022
  57. VAN 'T ERVE I, Medina JE, Leal A, Papp E, et al
    Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells.
    Clin Cancer Res. 2022 Dec 19:CCR-22-2538. doi: 10.1158/1078-0432.CCR-22-2538.
    >> Share

  58. ZHANG W, Auguste A, Liao X, Walterskirchen C, et al
    A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors.
    Clin Cancer Res. 2022;28:5190-5201.
    >> Share

    November 2022
  59. WEITZ J, Hurtado de Mendoza T, Tiriac H, Lee J, et al
    An Ex Vivo Organotypic Culture Platform for Functional Interrogation of Human Appendiceal Cancer Reveals a Prominent and Heterogenous Immunological Landscape.
    Clin Cancer Res. 2022;28:4793-4806.
    >> Share

    October 2022
  60. SATHE A, Mason K, Grimes SM, Zhou Z, et al
    Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor associated SPP1+ macrophages and fibroblasts.
    Clin Cancer Res. 2022 Oct 14. pii: 709778. doi: 10.1158/1078-0432.CCR-22-2041.
    >> Share

    September 2022
  61. VIDAL J, Fernandez-Rodriguez MC, Casadevall D, Garcia-Alfonso P, et al
    Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study.
    Clin Cancer Res. 2022 Sep 8. pii: 709130. doi: 10.1158/1078-0432.CCR-22-1696.
    >> Share

    August 2022
  62. WANG F, He MM, Xiao J, Zhang YQ, et al
    A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab in unresectable untreated metastatic colorectal cancer.
    Clin Cancer Res. 2022 Aug 5. pii: 707466. doi: 10.1158/1078-0432.CCR-22-0655.
    >> Share

    July 2022
  63. DURINIKOVA E, Reilly NM, Buzo K, Mariella E, et al
    Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer.
    Clin Cancer Res. 2022 Jul 26:OF1-OF16. doi: 10.1158/1078-0432.CCR-22-0875.
    >> Share

  64. MANNING-GEIST BL, Liu YL, Devereaux KA, Da Cruz Paula A, et al
    Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles.
    Clin Cancer Res. 2022 Jul 18. pii: 707055. doi: 10.1158/1078-0432.CCR-22-0713.
    >> Share

    May 2022
  65. CHIDA K, Kawazoe A, Suzuki T, Kawazu M, et al
    Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy.
    Clin Cancer Res. 2022;28:2110-2117.
    >> Share

    April 2022
  66. HUBBARD JM, Toke ER, Moretto R, Graham RP, et al
    Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase 1b study.
    Clin Cancer Res. 2022 Apr 26. pii: 694763. doi: 10.1158/1078-0432.CCR-22-0112.
    >> Share

  67. SIEMENS H, Neumann J, Jackstadt R, Mansmann U, et al
    Correction: Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and beta-Catenin Predicts Distant Metastasis of Colon Cancer.
    Clin Cancer Res. 2022;28:1739.
    >> Share

  68. LIU Z, Wei P, Yang Y, Cui W, et al
    Correction: BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs.
    Clin Cancer Res. 2022;28:1738.
    >> Share

  69. FUJII S, Kotani D, Hattori M, Nishihara M, et al
    Rapid screening using pathomorphological interpretation to detect BRAFV600E mutation and microsatellite instability in colorectal cancer.
    Clin Cancer Res. 2022 Apr 1. pii: 694119. doi: 10.1158/1078-0432.CCR-21-4391.
    >> Share

    March 2022
  70. BANDO H, Tsukada Y, Inamori K, Togashi Y, et al
    Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
    Clin Cancer Res. 2022;28:1136-1146.
    >> Share

  71. SEEBER A, Battaglin F, Zimmer K, Kocher F, et al
    Comprehensive analysis of R-spondin fusions and RNF43 mutations implicate novel therapeutic options in colorectal cancer.
    Clin Cancer Res. 2022 Mar 7. pii: 681556. doi: 10.1158/1078-0432.CCR-21-3018.
    >> Share

    February 2022
  72. INNOCENTI F, Yazdani A, Rashid N, Qu X, et al
    Tumor immunogenomic features determine outcomes in metastatic colorectal cancer patients treated with standard-of-care combinations of bevacizumab and cetuximab.
    Clin Cancer Res. 2022 Feb 17. pii: 681557. doi: 10.1158/1078-0432.CCR-21-3202.
    >> Share

    January 2022
  73. SCHWARTZ CJ, da Silva EM, Marra A, Gazzo AM, et al
    Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.
    Clin Cancer Res. 2022;28:404-413.
    >> Share

  74. CRUZ-DUARTE R, de Almeida CR, Negrao M, Fernandes A, et al
    Predictive and therapeutic implications of a novel PLCgamma1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer.
    Clin Cancer Res. 2022 Jan 3. pii: 1078-0432.CCR-21-1992.
    >> Share

    December 2021
  75. NIXON AB, Sibley AB, Liu Y, Hatch AJ, et al
    Plasma protein markers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: Results from CALGB 80405 (Alliance).
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-2389.
    >> Share

  76. GRAHAM LS, Pritchard CC, Schweizer MT
    Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.
    Clin Cancer Res. 2021;27:6662-6665.
    >> Share

  77. CATENACCI DVT
    Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA.
    Clin Cancer Res. 2021;27:6281-6283.
    >> Share

    November 2021
  78. MORRIS VK, George TJ
    Using circulating tumor DNA for colon cancer adjuvant therapy: to be or not to be?
    Clin Cancer Res. 2021 Nov 30. pii: 1078-0432.CCR-21-3564.
    >> Share

  79. CHAKRABORTY S, Ecker BL, Seier K, Aveson VG, et al
    Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care.
    Clin Cancer Res. 2021;27:5891-5899.
    >> Share

    October 2021
  80. FOUNTZILAS C, Bajor DL, Mukherjee S, Saltzman J, et al
    Phase Ib/II study of Cetuximab Plus Pembrolizumab in Patients with Advanced RAS wild-type Colorectal Cancer.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1650.
    >> Share

  81. HENRIKSEN TV, Tarazona N, Frydendahl A, Reinert T, et al
    Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences.
    Clin Cancer Res. 2021 Oct 8. pii: 1078-0432.CCR-21-2404.
    >> Share

    September 2021
  82. KAWAZOE A, Itahashi K, Yamamoto N, Kotani D, et al
    TAS-116 plus nivolumab in patients with colorectal cancer and other solid tumors: an, open-label, dose-finding, and expansion phase Ib trial (EPOC1704).
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1929.
    >> Share

  83. MARISA L, Blum Y, Taieb J, Ayadi M, et al
    Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer.
    Clin Cancer Res. 2021;27:4768-4780.
    >> Share

  84. CASAK SJ, Marcus L, Fashoyin-Aje L, Mushti SL, et al
    FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma.
    Clin Cancer Res. 2021;27:4680-4684.
    >> Share

    June 2021
  85. CLEARY JM, Wang V, Heist RS, Kopetz ES, et al
    Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.
    Clin Cancer Res. 2021;27:2996-3004.
    >> Share

    May 2021
  86. VIDAL J, Casadevall D, Bellosillo B, Pericay C, et al
    Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial.
    Clin Cancer Res. 2021;27:2890-2898.
    >> Share

  87. BOROWSKY J, Haruki K, Lau MC, Dias Costa A, et al
    Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment.
    Clin Cancer Res. 2021;27:2816-2826.
    >> Share

    April 2021
  88. YOUNG C, Wood HM, Fuentes Balaguer A, Bottomley D, et al
    Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy.
    Clin Cancer Res. 2021;27:2246-2254.
    >> Share

    March 2021
  89. ZHAO M, Scott S, Evans KW, Yuca E, et al
    Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
    Clin Cancer Res. 2021;27:1681-1694.
    >> Share

  90. SINGH H, Li YY, Spurr LF, Shinagare AB, et al
    Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
    Clin Cancer Res. 2021;27:1695-1705.
    >> Share

  91. YI Y, Shen L, Shi W, Xia F, et al
    Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study.
    Clin Cancer Res. 2021;27:1329-1340.
    >> Share

  92. LATHAM A, Shia J, Patel Z, Reidy-Lagunes DL, et al
    Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma.
    Clin Cancer Res. 2021;27:1429-1437.
    >> Share

    January 2021
  93. MORRIS JS, Luthra R, Liu Y, Duose DY, et al
    Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting.
    Clin Cancer Res. 2021;27:120-130.
    >> Share

  94. ZHOU J, Wang C, Lin G, Xiao Y, et al
    Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study.
    Clin Cancer Res. 2021;27:301-310.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016